Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Gilead Sciences Inc., profitability ratios (quarterly data)
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
Gross Profit Margin
Gilead Sciences Inc., gross profit margin calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Gross profit on product sales | 5,930 | 5,352 | 4,003 | 4,498 | 4,113 | 4,481 | 4,607 | 4,243 | 4,111 | 4,369 | 4,344 | 4,000 | 4,581 | 5,370 | 5,920 | 5,420 | 6,141 | 6,276 | 6,787 | 6,488 | ||||||
| Product sales | 7,328 | 6,493 | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | 81.23% | 78.72% | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 50.49% | 50.18% | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | — | — | — | ||||||
| AbbVie Inc. | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | — | — | — | ||||||
| Amgen Inc. | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | 69.90% | 70.10% | 70.86% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | — | — | — | ||||||
| Eli Lilly & Co. | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | — | — | — | ||||||
| Illumina Inc. | 68.01% | 69.02% | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | — | — | — | ||||||
| Johnson & Johnson | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | — | — | — | ||||||
| Merck & Co. Inc. | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | — | — | — | ||||||
| Pfizer Inc. | 79.26% | 79.86% | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 88.14% | 88.01% | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | — | — | — | ||||||
| Zoetis Inc. | 69.18% | 69.64% | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | — | — | — | ||||||
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Gross profit margin = 100
× (Gross profit on product salesQ4 2020
+ Gross profit on product salesQ3 2020
+ Gross profit on product salesQ2 2020
+ Gross profit on product salesQ1 2020)
÷ (Product salesQ4 2020
+ Product salesQ3 2020
+ Product salesQ2 2020
+ Product salesQ1 2020)
= 100 × (5,930 + 5,352 + 4,003 + 4,498)
÷ (7,328 + 6,493 + 5,067 + 5,467)
= 81.23%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Operating Profit Margin
Gilead Sciences Inc., operating profit margin calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Income (loss) from operations | 2,651 | 2,001 | (2,983) | 2,402 | 1,093 | (1,473) | 2,430 | 2,237 | 1,144 | 2,623 | 2,280 | 2,153 | 2,291 | 3,812 | 4,254 | 3,767 | 4,045 | 4,399 | 4,538 | 4,651 | ||||||
| Product sales | 7,328 | 6,493 | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | 16.72% | 11.01% | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 15.48% | 13.39% | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | — | — | — | ||||||
| AbbVie Inc. | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | — | — | — | ||||||
| Amgen Inc. | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | 28.63% | 28.59% | 23.43% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | — | — | — | ||||||
| Eli Lilly & Co. | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | — | — | — | ||||||
| Illumina Inc. | 17.91% | 22.08% | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | — | — | — | ||||||
| Johnson & Johnson | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | — | — | — | ||||||
| Merck & Co. Inc. | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | — | — | — | ||||||
| Pfizer Inc. | 19.47% | 24.77% | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 46.03% | 44.43% | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | — | — | — | ||||||
| Zoetis Inc. | 33.62% | 33.87% | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | — | — | — | ||||||
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ4 2020
+ Income (loss) from operationsQ3 2020
+ Income (loss) from operationsQ2 2020
+ Income (loss) from operationsQ1 2020)
÷ (Product salesQ4 2020
+ Product salesQ3 2020
+ Product salesQ2 2020
+ Product salesQ1 2020)
= 100 × (2,651 + 2,001 + -2,983 + 2,402)
÷ (7,328 + 6,493 + 5,067 + 5,467)
= 16.72%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Net Profit Margin
Gilead Sciences Inc., net profit margin calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | 1,551 | 360 | (3,339) | 1,551 | 2,696 | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | ||||||
| Product sales | 7,328 | 6,493 | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | 0.51% | 5.56% | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 12.99% | 10.50% | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | — | — | — | ||||||
| AbbVie Inc. | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | — | — | — | ||||||
| Amgen Inc. | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | — | — | — | ||||||
| Eli Lilly & Co. | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | — | — | — | ||||||
| Illumina Inc. | 20.25% | 19.70% | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | — | — | — | ||||||
| Johnson & Johnson | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | — | — | — | ||||||
| Merck & Co. Inc. | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | — | — | — | ||||||
| Pfizer Inc. | 22.95% | 17.85% | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 43.70% | 44.91% | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | — | — | — | ||||||
| Zoetis Inc. | 24.54% | 25.42% | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | — | — | — | ||||||
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Net profit margin = 100
× (Net income (loss) attributable to GileadQ4 2020
+ Net income (loss) attributable to GileadQ3 2020
+ Net income (loss) attributable to GileadQ2 2020
+ Net income (loss) attributable to GileadQ1 2020)
÷ (Product salesQ4 2020
+ Product salesQ3 2020
+ Product salesQ2 2020
+ Product salesQ1 2020)
= 100 × (1,551 + 360 + -3,339 + 1,551)
÷ (7,328 + 6,493 + 5,067 + 5,467)
= 0.51%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
Return on Equity (ROE)
Gilead Sciences Inc., ROE calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | 1,551 | 360 | (3,339) | 1,551 | 2,696 | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | ||||||
| Total Gilead stockholders’ equity | 18,202 | 17,445 | 18,027 | 22,067 | 22,525 | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 13.71% | 10.78% | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | — | — | — | ||||||
| AbbVie Inc. | 35.30% | 48.34% | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | — | — | — | ||||||
| Amgen Inc. | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | — | — | — | ||||||
| Eli Lilly & Co. | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | — | — | — | ||||||
| Illumina Inc. | 13.98% | 13.57% | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | — | — | — | ||||||
| Johnson & Johnson | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | — | — | — | ||||||
| Merck & Co. Inc. | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | — | — | — | ||||||
| Pfizer Inc. | 15.21% | 13.31% | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 31.22% | 33.08% | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | — | — | — | ||||||
| Zoetis Inc. | 43.46% | 46.17% | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | — | — | — | ||||||
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
ROE = 100
× (Net income (loss) attributable to GileadQ4 2020
+ Net income (loss) attributable to GileadQ3 2020
+ Net income (loss) attributable to GileadQ2 2020
+ Net income (loss) attributable to GileadQ1 2020)
÷ Total Gilead stockholders’ equity
= 100 × (1,551 + 360 + -3,339 + 1,551)
÷ 18,202 = 0.68%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |
Return on Assets (ROA)
Gilead Sciences Inc., ROA calculation (quarterly data)
| Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) attributable to Gilead | 1,551 | 360 | (3,339) | 1,551 | 2,696 | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | ||||||
| Total assets | 68,407 | 60,878 | 55,934 | 59,741 | 61,627 | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 | 65,381 | 70,283 | 64,662 | 60,263 | 57,701 | 56,977 | 56,609 | 49,980 | 47,765 | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| Abbott Laboratories | 6.20% | 4.90% | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | — | — | — | ||||||
| AbbVie Inc. | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | — | — | — | ||||||
| Amgen Inc. | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | — | — | — | ||||||
| Eli Lilly & Co. | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | — | — | — | ||||||
| Illumina Inc. | 8.65% | 8.62% | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | — | — | — | ||||||
| Johnson & Johnson | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | — | — | — | ||||||
| Merck & Co. Inc. | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | — | — | — | ||||||
| Pfizer Inc. | 6.23% | 4.85% | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 23.07% | 23.81% | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | — | — | — | ||||||
| Zoetis Inc. | 12.04% | 12.12% | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | — | — | — | ||||||
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
ROA = 100
× (Net income (loss) attributable to GileadQ4 2020
+ Net income (loss) attributable to GileadQ3 2020
+ Net income (loss) attributable to GileadQ2 2020
+ Net income (loss) attributable to GileadQ1 2020)
÷ Total assets
= 100 × (1,551 + 360 + -3,339 + 1,551)
÷ 68,407 = 0.18%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level. |